Just as vaccinations get under way in full force, a few indicators raise the question about whether the vaccine really is as well matched as was anticipated.
The PARP inhibitor received a Breakthrough Therapy Designation for metastatic castration-resistant prostate cancer based on data released from the GALAHAD study.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape. 
Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.
The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.
The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.
FDA Approves New PrEP Drug
The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.
Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.
FDA Testing Ranitidine
The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.
The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).
Oprah Promotes Vaccines
Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.
Findings published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) suggest that THC products are playing a role in the recent outbreak of lung injuries associated with e-cigarette and vape use.
Research Centers Launched with Focus on Alzheimer Drug Development
The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
+ Load More